Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market

Biotech company Actinogen has expanded clinical development for the company’s lead drug candidate ‘Xanamem’.

The company made the decision after an extensive scientific, commercial and testing review of the drug showed positive projections.

Xanamem is a drug aimed at treating impairment in neurological diseases such as Alzheimer’s, schizophrenia and bipolar disorder.

The drug targets raised cortisol levels in the brain and inhibits excess production of it.

Excessive cortisol production in the brain is common amongst mood disorder patients.

Xanamem has shown positive results on genetically identical mouse models and showed maintained improved cognitive function for 41 weeks.

Second phase trials of Alzheimer’s patients using Xanamem began in 2017.

The company estimates roughly 24 million Americans are living with mood disorders and this research shows significant market opportunity.

A specialist advisory board will be assigned to establish the company’s future clinical development plan for the drug.

Please see announcement attached

ACW by the numbers
More From The Market Herald
Bill Identity (ASX:BID) - Incoming CEO, Michele Garra (left)

" Bill Identity (ASX:BID) appoints Michele Garra as new CEO

Bill Identity (BID) has appointed a Telstra and Optus senior executive as its new Chief Executive Officer.
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Peppermint Innovation (ASX:PIL) - CEO and Managing Director, Chris Kain

" Peppermint Innovation (ASX:PIL) signs with payment gateway Dragonpay

Peppermint Innovation (PIL) has signed an agreement with one of the Philippines’ largest and most reliable online payment gateway platforms, Dragonpay.